44 results
Page 2 of 3
6-K
EX-99.1
5s8df2pqgg
5 Apr 23
Current report (foreign)
4:01pm
6-K
EX-99.1
la2ofv5o ty
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.1
zngzxu0fdn1po uo
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
6-K
EX-99.1
ut481jcik2s
3 May 21
Current report (foreign)
4:15pm
6-K
ljjqusf0qg u7a5
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
39yzo8e7u7rgtl i2gt
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
6-K
EX-99.1
xsj0axp
6 Aug 20
InflaRx to Present at Upcoming Virtual Investor Events
7:35am
6-K
EX-99.1
bba0brjt272o
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
kg5vk3hez lja64y
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
szdbnoxbrn1yd1jk
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.3
7df 645i5
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
20-F/A
rk8ojt nh
29 Mar 19
Annual report (foreign) (amended)
4:23pm
6-K
EX-99.1
l4lyeo k6ngimb0
14 Feb 19
Current report (foreign)
8:44am
6-K
EX-99.3
a3w6zhy6fqwrddu cj
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.1
xskgdd5
21 Sep 18
InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors
8:38am
424B4
bg0g0 eexx
7 May 18
Prospectus supplement with pricing info
4:47pm